- Prompted by a tough business climate and apparent buyer interest, thinly traded nano cap Metabolix (MBLX) announces that it is exploring strategic alternatives for its specialty biopolymers unit and its Yield10 crop science program.
- If a deal can be reached for the biopolymers business, the company may redirect resources on developing and commercializing Yield10 or it may jettison it as well. According to the company, negotiations with interested parties are underway.
- Metabolix is currently trying to secure additional capital before the end of the month. As of the end of March, it had only $5.3M in quick assets.
- Citing these developments, management will not be hosting a conference call to discuss Q1 results.